ACADIA Pharmaceuticals Inc (ACAD)
22.92
+1.64 +7.71%
NASDAQ
Oct 16, 20:00
Delayed 2m
USD
View All Key Stats
ACAD Key Stats
| Income Statement | |
| Revenue (TTM) | 185.07M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -2.03 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -251.68M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 93.76% |
| Profit Margin (Quarterly) | -110.9% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | Upgrade |
| Price and Valuation | |
| Market Cap | 2.865B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | 15.36 |
| PE Ratio (TTM) | -- |
| Price to Book Value | 10.82 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | Upgrade |
| Free Cash Flow (Quarterly) | -40.99M |
| Return on Equity (TTM) | Upgrade |
View All ACAD News
ACAD News
-
WireHeadlineTime (ET)
-
Yahoo10/16 08:02
-
Yahoo10/12 08:00
-
Yahoo10/10 13:30
-
MT Newswires10/10 12:57
-
Yahoo10/10 10:35
-
Yahoo10/08 16:05
-
Yahoo10/08 08:02
-
Yahoo09/27 08:08
-
Yahoo09/27 06:00
-
Yahoo09/26 15:07
View All Events
ACAD Events
| Date | Type | Description |
|---|---|---|
| 11/07/2018 17:00 EST | Misc | ACADIA Pharmaceuticals Inc Third Quarter Earnings Conference Call in 2018 |
| 11/07/2018 | Earnings | ACADIA Pharmaceuticals Inc Third Quarter Earnings in 2018 Release |
| 08/08/2018 17:00 EDT | Misc | ACADIA Pharmaceuticals Inc Second Quarter Earnings Conference Call in 2018 |
| 08/08/2018 | Earnings | ACADIA Pharmaceuticals Inc Second Quarter Earnings Results in 2018 |
| 06/06/2018 | Misc | ACADIA Pharmaceuticals Inc Annual General Meeting in 2017 |
| 05/04/2018 08:30 EDT | Misc | ACADIA Pharmaceuticals Inc First Quarter Earnings Conference Call in 2018 |
| 05/04/2018 | Earnings | ACADIA Pharmaceuticals Inc First Quarter Earnings Results in 2018 |
| 02/27/2018 17:00 EST | Misc | ACADIA Pharmaceuticals Inc Fourth Quarter Earnings Conference Call in 2017 |
| 02/27/2018 | Earnings | ACADIA Pharmaceuticals Inc Fourth Quarter Earnings Results in 2017 |
| 02/27/2018 | Misc | ACADIA Pharmaceuticals Inc Annual Report in 2017 |
ACAD Fundamentals
Income Statement View Statement
ACAD Ratings
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
Advertisement
ACAD One Page Reports
- One Page Report Download
ACAD Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 22.92 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Edit
Profile
- URL: http://www.acadia-pharm.com
- Investor Relations URL: http://ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
- HQ State/Province: California
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Growth
- Next Earnings Release: Nov. 07, 2018
- Last Earnings Release: Aug. 08, 2018
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson’s, Alzheimer’s and schizophrenia.
ACAD Excel Add-In Codes
- Name: =YCI("ACAD","name")
- Description: =YCI("ACAD","description")
- Sector: =YCI("ACAD","sector")
- Industry: =YCI("ACAD","industry")
- Est. Current Fiscal Year End: =YCI("ACAD","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Other ACAD Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- ACAD Tweets Stocktwits
Advertisement
